Kenneth Williams

Honorary Professor

Research Interests:
Interests span the general area of conducting of clinical trials of new medicines (design, ethical issues, endpoints including surrogate outcomes), including complementary medicines complementary medicines. A particular focus is on arthritis, gout and diabetes. Drug metabolism and disposition and pharmacokinetics are also interests.

Broad Research Areas:
Clinical Research, Pharmacology, Metabolism, Inflammation, Diabetes

Society Memberships & Professional Activities:
Society memberships:, ASCEPT, ARA, DIA, ARCS, , Professional Activities/Appointments:, Module coordinator and tutor Postgraduate Studies in Drug Development, UNSW, Deputy Director Department of Clinical Pharmacology, St Vincent's Hospital

Specific Research Keywords:
Clinical Pharmacology, Drugs, Drug Safety, Gout, Diabetes and Endocrinology

publications

Journal articles
add
Kamel B; Williams KM; Graham GG; Norris RLG; Stocker SL; Carland JE; Pile KD; Day RO, 2019, 'Determination of febuxostat in human plasma by high performance liquid chromatography (HPLC) with fluorescence-detection', Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, vol. 1126-1127, http://dx.doi.org/10.1016/j.jchromb.2019.121764
2019
Day RO; Lau W; Stocker SL; Aung E; Coleshill MJ; Schulz M; Bechara J; Carland JE; Graham GG; Williams KM; McLachlan AJ, 2019, 'Management of gout in older people', Journal of Pharmacy Practice and Research, vol. 49, pp. 90 - 97, http://dx.doi.org/10.1002/jppr.1511
2019
Abdel Shaheed C; Carland JE; Graham GG; Stocker SL; Smith G; Hicks M; Williams KM; Furlong T; Macdonald P; Greenfield JR; Smith FC; Chowdhury G; Day RO, 2019, 'Is the use of metformin in patients undergoing dialysis hazardous for life? A systematic review of the safety of metformin in patients undergoing dialysis', British Journal of Clinical Pharmacology, vol. 85, pp. 2772 - 2783, http://dx.doi.org/10.1111/bcp.14107
2019
Kumar SS; McManus H; Radovich T; Greenfield JR; Viardot A; Williams KM; Cronin P; Day RO, 2018, 'Interrogation of a longitudinal, national pharmacy claims dataset to explore factors that predict the need for add-on therapy in older and socioeconomically disadvantaged Australians with type 2 diabetes mellitus patients (T2DM)', European Journal of Clinical Pharmacology, vol. 74, pp. 1327 - 1332, http://dx.doi.org/10.1007/s00228-018-2506-5
2018
Duong JK; Kroonen MYAM; Kumar SS; Heerspink HL; Kirkpatrick CM; Graham GG; Williams KM; Day RO, 2017, 'A dosing algorithm for metformin based on the relationships between exposure and renal clearance of metformin in patients with varying degrees of kidney function', European Journal of Clinical Pharmacology, vol. 73, pp. 981 - 990, http://dx.doi.org/10.1007/s00228-017-2251-1
2017
Day RO; Kannangara DRW; Stocker SL; Carland JE; Williams KM; Graham GG, 2017, 'Allopurinol: insights from studies of dose–response relationships', Expert Opinion on Drug Metabolism and Toxicology, vol. 13, pp. 449 - 462, http://dx.doi.org/10.1080/17425255.2017.1269745
2017
Kamel B; Graham GG; Williams KM; Pile KD; Day RO, 2017, 'Clinical Pharmacokinetics and Pharmacodynamics of Febuxostat', Clinical Pharmacokinetics, vol. 56, pp. 459 - 475, http://dx.doi.org/10.1007/s40262-016-0466-4
2017
Day RO; Frensham LJ; Nguyen AD; Baysari MT; Aung E; Lau AYS; Zwar N; Reath J; Laba T; Li L; McLachlan A; Runciman WB; Buchbinder R; Clay-Williams R; Coiera E; Braithwaite J; McNeil HP; Hunter DJ; Pile KJ; Portek I; Williams KM; Westbrook JI, 2017, 'Effectiveness of an electronic patient-centred self-management tool for gout sufferers: A cluster randomised controlled trail protocol', BMJ Open, vol. 7, http://dx.doi.org/10.1136/bmjopen-2017-017281
2017
Kannangara DRW; Graham GG; Wright DFB; Stocker SL; Portek I; Pile KD; Barclay ML; Williams KM; Stamp LK; Day RO, 2017, 'Individualising the dose of allopurinol in patients with gout', British Journal of Clinical Pharmacology, vol. 83, pp. 2015 - 2026, http://dx.doi.org/10.1111/bcp.13307
2017
Kannangara DRW; Phipps-Green AJ; Dalbeth N; Stamp LK; Williams KM; Graham GG; Day RO; Merriman TR, 2016, 'Hyperuricaemia: Contributions of urate transporter ABCG2 and the fractional renal clearance of urate', Annals of the Rheumatic Diseases, vol. 75, pp. 1363 - 1366, http://dx.doi.org/10.1136/annrheumdis-2015-208111
2016
Day RO; Kamel B; Kannangara DRW; Williams KM; Graham GG, 2016, 'Xanthine oxidoreductase and its inhibitors: Relevance for gout', Clinical Science, vol. 130, pp. 2167 - 2180, http://dx.doi.org/10.1042/CS20160010
2016
Smith FC; Kumar SS; Furlong TJ; Gangaram SV; Greenfield JR; Stocker SL; Graham GG; Williams KM; Day RO, 2016, 'Pharmacokinetics of Metformin in Patients Receiving Regular Hemodiafiltration', American Journal of Kidney Diseases, vol. 68, pp. 990 - 992, http://dx.doi.org/10.1053/j.ajkd.2016.08.017
2016
Kannangara DRW; Graham GG; Williams KM; Day RO, 2016, 'Effect of xanthine oxidase inhibitors on the renal clearance of uric acid and creatinine', Clinical Rheumatology, vol. 35, pp. 2375 - 2376, http://dx.doi.org/10.1007/s10067-015-3165-x
2016
Martinello M; Schteinman A; Alavi M; Williams K; Dore GJ; Day R; Matthews GV, 2016, 'The impact of ribavirin plasma concentration on the efficacy of the interferon-sparing regimen, sofosbuvir and ribavirin', ANTIVIRAL THERAPY, vol. 21, pp. 127 - 132, http://dx.doi.org/10.3851/IMP2984
2016
Moon J; Kumar SS; Graham GG; Baysari MT; Williams KM; Chen W; Viardot A; Greenfield JR; Day RO, 2016, 'Trends in metformin utilisation and dose appropriateness in Australia', European Journal of Clinical Pharmacology, vol. 72, pp. 1489 - 1496, http://dx.doi.org/10.1007/s00228-016-2117-y
2016
Vaccher S; Kannangara DRW; Baysari MT; Reath J; Zwar N; Williams KM; Day RO, 2016, 'Barriers to care in gout: From prescriber to patient', Journal of Rheumatology, vol. 43, pp. 144 - 149, http://dx.doi.org/10.3899/jrheum.150607
2016
Rasheed H; McKinney C; Stamp LK; Dalbeth N; Topless RK; Day R; Kannangara D; Williams K; Smith M; Janssen M; Jansen TL; Joosten LA; Radstake TR; Riches PL; Tausche AK; Lioté F; Lu L; Stahl EA; Choi HK; So A; Merriman TR, 2016, 'The toll-like receptor 4 (TLR4) variant rs2149356 and risk of gout in European and polynesian sample sets', PLoS ONE, vol. 11, http://dx.doi.org/10.1371/journal.pone.0147939
2016
McKinney C; Stamp LK; Dalbeth N; Topless RK; Day RO; Kannangara DRW; Williams KM; Janssen M; Jansen TL; Joosten LA; Radstake TR; Riches PL; Tausche AK; Lioté F; So A; Merriman TR, 2015, 'Multiplicative interaction of functional inflammasome genetic variants in determining the risk of gout', Arthritis Research and Therapy, vol. 17, http://dx.doi.org/10.1186/s13075-015-0802-3
2015
Chung WH; Chang WC; Stocker SL; Juo CG; Graham GG; Lee MHH; Williams KM; Tian YC; Juan KC; Wu YJJ; Yang CH; Chang CJ; Lin YJ; Day RO; Hung SI, 2015, 'Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: The impact of renal insufficiency, high plasma levels of oxypurinol and granulysin', Annals of the Rheumatic Diseases, vol. 74, pp. 2157 - 2164, http://dx.doi.org/10.1136/annrheumdis-2014-205577
2015
Hmar RC; Kannangara DRW; Ramasamy SN; Baysari MT; Williams KM; Day RO, 2015, 'Understanding and improving the use of allopurinol in a teaching hospital', Internal Medicine Journal, vol. 45, pp. 383 - 390, http://dx.doi.org/10.1111/imj.12701
2015
Duong JK; Kumar SS; Furlong TJ; Kirkpatrick CM; Graham GG; Greenfield JR; Williams KM; Day RO, 2015, 'The pharmacokinetics of metformin and concentrations of haemoglobin A1C and lactate in Indigenous and non-Indigenous Australians with type 2 diabetes mellitus', British Journal of Clinical Pharmacology, vol. 79, pp. 617 - 623, http://dx.doi.org/10.1111/bcp.12525
2015
Merriman TR; Stamp LK; Dalbeth N; Topless R; Day R; Kannangara D; Williams K; Janssen M; Jansen T; Joosten LA; Radstake T; Riches PL; Tausche A-K; Liote F; So A; McKinney C, 2015, 'Epistatic Interaction of Functional Inflammasome Genetic Variants in Determining the Risk of Gout', ARTHRITIS & RHEUMATOLOGY, vol. 67, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000370860204715&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2015
Rasheed H; Topless R; Day R; Kannangara D; Williams K; Bradbury L; Brown M; Hill C; Lester S; Rischmueller M; Smith M; Andres M; Bardin T; Doherty M; Janssen M; Jansen T; Joosten L; Perez-Ruiz F; Radstake T; Riches PL; Roddy E; Tausche A-K; Stamp LK; Dalbeth N; Liote F; So A; McKinney C; Merriman TR, 2014, 'Association of the Toll-like Receptor 4 (TLR4) Gene with Gout.', ARTHRITIS & RHEUMATOLOGY, vol. 66, pp. S1294 - S1295, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344384906196&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2014
Ghosh D; Williams KM; Graham GG; Nair P; Buscher H; Day RO, 2014, 'Multiple episodes of aspirin overdose in an individual patient: A case report', Journal of Medical Case Reports, vol. 8, pp. 1 - 5, http://dx.doi.org/10.1186/1752-1947-8-374
2014
Kannangara DRW; Graham GG; Williams KM; Day RO, 2014, 'Hypouricemic effects of prednisone and allopurinol: An uneven playing field?', Canadian Journal of Cardiology, vol. 30, pp. 376.e1, http://dx.doi.org/10.1016/j.cjca.2013.04.015
2014
Kannangara DRW; Ramasamy SN; Ray JE; Jones G; Graham GG; Williams KM; Day RO, 2013, 'An audit of a therapeutic drug monitoring service for allopurinol therapy', Therapeutic Drug Monitoring, vol. 35, pp. 863 - 866, http://dx.doi.org/10.1097/FTD.0b013e318299920a
2013
Wong C; Kumar SS; Graham GG; Begg EJ; Chin P; Brett J; Ray J; Marriott D; Williams KM; Day RO, 2013, 'Comparing dose prediction software used to manage gentamicin dosing', Internal Medicine Journal, vol. 43, pp. 519 - 525, http://dx.doi.org/10.1111/imj.12067
2013
Brett J; Chong O; Graham GG; Ray J; Marriott D; Williams KM; Day RO, 2013, 'Antifungal Use and Therapeutic Monitoring of Plasma Concentrations of Itraconazole in Heart and Lung Transplantation Patients.', Therapeutic Drug Monitoring, vol. 35, pp. 133 - 136, http://dx.doi.org/10.1097/FTD.0b013e318275fe69
2013
Ramasamy SN; Korb-Wells CS; Kannangara DRW; Smith MWH; Wang N; Roberts DM; Graham GG; Williams KM; Day RO, 2013, 'Allopurinol hypersensitivity: A systematic review of all published cases, 1950-2012', Drug Safety, vol. 36, pp. 953 - 980, http://dx.doi.org/10.1007/s40264-013-0084-0
2013
Lee M-H; Stocker S; Williams KM; Day RO, 2013, 'HLA-B*5801 should be used to screen for risk of Stevens-Johnson Syndrome (SJS) in family members of Han-Chinese patients commencing allopurinol therapy', Journal of Rheumatology, vol. 40, pp. 96 - 97, http://dx.doi.org/10.3899/jrheum.120803
2013
Day R; Lee H; Graham G; Williams K, 2013, 'Benzbromarone: Availability for general prescribing in New Zealand (a response to letters by Dr Lance Gravatt on benzbromarone)', New Zealand Medical Journal, vol. 126, pp. 124 - 126
2013
Kannangara D; Roberts DM; Furlong TJ; Graham GG; Williams K; Day RO, 2012, 'Oxypurinol, allopurinol and allopurinol-1-riboside in plasma following an acute overdose of allopurinol in a patient with advanced chronic kidney disease', British Journal of Clinical Pharmacology, vol. 73, pp. 828 - 829, http://dx.doi.org/10.1111/j.1365-2125.2011.04147.x
2012
Stocker S; Mclachlan AJ; Savic RM; Kirkpatrick CM; Graham GG; Williams KM; Day RO, 2012, 'The pharmacokinetics of oxypurinol in people with gout', British Journal of Clinical Pharacology, vol. 74, pp. 477 - 489, http://dx.doi.org/10.1111/j.1365-2125.2012.04207.x
2012
Lee M-H; Stocker S; Anderson JM; Phillips EJ; Nolan DL; Williams KM; Graham GG; Sullivan JR; Day RO, 2012, 'Initiating allopurinol therapy: Do we need to know the patient's human leucocyte antigen status?', Internal Medicine Journal, vol. 42, pp. 411 - 416, http://dx.doi.org/10.1111/j.1445-5994.2011.02567.x
2012
Duong JK; Roberts DM; Furlong TJ; Kumar SS; Greenfield JR; Kirkpatrick CM; Graham GG; Williams KM; Day RO, 2012, 'Metformin therapy in patients with chronic kidney disease', Diabetes Obesity and Metabolism, vol. 14, pp. 963 - 965, http://dx.doi.org/10.1111/j.1463-1326.2012.01617.x
2012
Kannangara DRW; Ramasamy SN; Indraratna P; Stocker S; Graham GG; Jones G; Portek I; Williams KM; Day RO, 2012, 'Fractional clearance of urate: Validation of measurement in spot urine samples in healthy subjects and gouty patients', Arthritis Research and Therapy, vol. 14, pp. R189 - R197, http://dx.doi.org/10.1186/ar4020
2012
Milder T; Lipworth WL; Williams KM; Ritchie JE; Day RO, 2011, '"It looks after me": how older patients make decisions about analgesics for osteoarthritis.', Arthritis Care and Research, vol. 63, pp. 1280 - 1286, http://dx.doi.org/10.1002/acr.20514
2011
Graham GG; Punt J; Manit A; Day RO; Doogue MP; Duong JK; Furlong TJ; Greenfield JR; Greenup L; Carl m kirkpatrick CM; Ray J; Timmins P; Williams KM, 2011, 'Clinical pharmacokinetics of metforim', Clinical Pharmacokinetics, vol. 50, pp. 81 - 98, http://dx.doi.org/10.2165/11534750-000000000-00000
2011
Wang N; Lipworth WL; Ritchie JE; Williams K; Day RO, 2011, 'Eliciting views of Australian pharmaceutical industry employees on collaboration and the concept of Quality Use of Medicines', Internal Medicine Journal, vol. 41, pp. 314 - 320, http://dx.doi.org/10.1111/j.1445-5994.2010.02239.x
2011
Ng DY; Stocker SL; Graham GG; Williams KM; Day RO, 2011, 'Lack of effect of hydrochlorothiazide and low-dose aspirin on the renal clearance of urate and oxypurinol after a single dose of allopurinol in normal volunteers', European Journal of Clinical Pharmacology, vol. 67, pp. 709 - 713, http://dx.doi.org/10.1007/s00228-010-0963-6
2011
Milder T; Williams K; Ritchie JE; Lipworth WL; Day RO, 2011, 'Use of NSAIDs for osteoarthritis amongst older-aged primary care patients: Engagement with information and perceptions of risk', Age and Ageing, vol. 40, pp. 254 - 259, http://dx.doi.org/10.1093/ageing/afq160
2011
Stocker SL; Graham GG; McLachlan AJ; Williams K; Day RO, 2011, 'Pharmacokinetic and Pharmacodynamic interaction between allopurinol and probenecid in patients with gout', Journal of Rheumatology, vol. 38, pp. 904 - 910, http://dx.doi.org/10.3899/jrheum.101160
2011
Indraratna P; Stocker SL; Williams KM; Graham GG; Jones G; Day RO, 2010, 'A proposal for identifying the low renal uric acid clearance phenotype', Arthritis Research and Therapy, vol. 12, pp. 149 - 151, http://dx.doi.org/10.1186/ar3191
2010
Wallace H; Graham GG; Williams K; Day RO, 2010, 'A risk-benefit assessment of paracetamol (acetaminophen) combined with caffeine', Pain Medicine, vol. 11, pp. 951 - 965, http://dx.doi.org/10.1111/j.1526-4637.2010.00867.x
2010
Stocker S; Franklin M; Anderson JM; Pillans PI; Williams K; McLachlan AJ; Day RO; taylor P, 2010, 'Measurement of urinary oxypurinol by high performance liquid chromatography-tandem mass spectrometry', Journal of Chromatography, vol. 878, pp. 2363 - 2368, http://dx.doi.org/10.1016/j.jchromb.2010.07.017
2010
Abdul M; Jiang XM; Williams KM; Day RO; Roufogalis B; Liauw WS; Xu H; Matthias A; Lehmann RP; McLachlan AJ, 2010, 'Pharmacokinetic and pharmacodynamic interactions of echinacea and policosanol with warfarin in healthy subjects', British Journal of Clinical Pharmacology, vol. 69, pp. 508 - 515, http://dx.doi.org/10.1111/j.1365-2125.2010.03620.x
2010
Day RO; Liauw WS; Tozer L; McElduff P; Beckett RJ; Williams K, 2010, 'A double-blind, placebo-controlled study of the short term effects of a spring water supplemented with magnesium bicarbonate on acid/base balance, bone metabolism and cardiovascular risk factors in postmenpausal women', BMC Research Notes, vol. 3, pp. 1 - 8, http://dx.doi.org/10.1186/1756-0500-3-180
2010
Indraratna P; Williams KM; Graham GG; Day RO, 2009, 'Hyperuricemia, Cardiovascular Disease and the Metabolic Syndrome', The Journal of Rheumatology, vol. 36, pp. 2842 - 2843, http://dx.doi.org/10.3899/jrheum.090500
2009
Pett SL; Mccarthy M; Cooper DA; MacRae K; Tendolkar A; Norris R; Strizki J; Williams KM; Emery S, 2009, 'A Phase I study to explore the activity and safety of SCH532706, a small molecule chemokine receptor-5 antagonist in HIV type-1-infected patients', Antiviral Therapy, vol. 14, pp. 111 - 115
2009
Xu H; Liauw WS; Murray M; Day RO; Mclachlan AJ, 2008, 'Effects of St John's wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazide', British Journal of Pharmacology, vol. 153, pp. 1579 - 1586, http://dx.doi.org/10.1038/sj.bjp.0707685
2008
Lu CY; Macneill P; Williams K; Day R, 2008, 'Access to high cost medicines in Australia: Ethical perspectives', Australia and New Zealand Health Policy, vol. 5, http://dx.doi.org/10.1186/1743-8462-5-4
2008
Abdul M; Jiang XM; Day RO; Roufogalis B; Liauw WS; Xu H; Mclachlan AJ, 2008, 'Pharmacodynamic interaction of warfarin with cranberry but not with garlic in healthy subjects', British Journal of Pharmacology, vol. 154, pp. 1691 - 1700, http://dx.doi.org/10.1038/bjp.2008.210
2008
McLachlan AJ; Day RO; Williams KM; Graham GG, 2008, 'Maximising gout therapy', Australian Journal of Pharmacy, vol. 89, pp. 86 - 88
2008
Lu CY; Williams KM; Day RO, 2008, 'Access to biologic medicines for the treatment of rheumatic diseases: lessons from Australia', International Journal of Rheumatology, vol. 11, pp. 11 - 14, http://dx.doi.org/10.1111/j.1756-185X.2008.00322.x
2008
Stocker S; Williams KM; Mclachlan AJ; Graham GG; Day RO, 2008, 'Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjects', Clinical Pharmacokinetics, vol. 47, pp. 111 - 118, http://dx.doi.org/10.2165/00003088-200847020-00004
2008
Burrell C; Booy R; Wood N; Egan AM; Taverner D; Williams K; Liauw W; Moskwa A; Pepin-Covatta S; Saville M, 2008, 'Immunogenicity of a reduced dose of A/H3N2 in the 2005 southern hemisphere formulation of inactivated split influenza vaccine', Influenza and other Respiratory Viruses, vol. 2, pp. 93 - 98, http://dx.doi.org/10.1111/j.1750-2659.2008.00039.x
2008
Lee M; Graham GG; Williams KM; Day RO, 2008, 'A benefit-risk assessment of benzbromarone in the treatment of gout - was its withdrawal from the market in the best interest of patients?', Drug Safety, vol. 31, pp. 643 - 665, http://dx.doi.org/10.2165/00002018-200831080-00002
2008
Lu C; Ritchie JE; Williams KM; Day RO, 2007, 'The views of stakeholders on controlled access schemes for high-cost antirheumatic biological medicines in Australia', Australia and New Zealand Health Policy, vol. 4, http://dx.doi.org/10.1186/1743-8462-4-26
2007
Day RO; Williams KM, 2007, 'Open-label extension studies - Do they provide meaningful information on the safety of new drugs?', Drug Safety, vol. 30, pp. 93 - 105, http://dx.doi.org/10.2165/00002018-200730020-00001
2007
Lu CY; Williams KM; Day RO, 2007, 'The funding and use of high-cost medicines in Australia: The example of anti-rheumatic biological medicines', Australia and New Zealand Health Policy, vol. 4, http://dx.doi.org/10.1186/1743-8462-4-2
2007
Day RO; Graham G; Williams K, 2007, 'Fenofibratewarfarin interaction [1]', Australian Prescriber, vol. 30, pp. 32
2007
Winston A; Mallon PW; Satchell C; MacRae K; Williams KM; Schutz M; Law MG; Cooper DA; Emery S, 2007, 'The safety, efficacy, and pharmacokinetic profile of a switch in antiretroviral therapy to saquinavir, ritonavir, and atazanavir alone for 48 weeks and a switch in the saquinavir formulation', Clinical Infectious Diseases, vol. 44, pp. 1475 - 1483, http://dx.doi.org/10.1086/517507
2007
Lu CY; Williams KM; Day RO, 2007, 'Has the use of disease-modifying anti-rheumatic drugs changed as a consequence of controlled access to high-cost biological agents through the Pharmaceutical Benefits Scheme?', Internal Medicine Journal, vol. 37, pp. 601 - 606, http://dx.doi.org/10.1111/j.1445-5994.2007.01396.x
2007
Day RO; Graham GG; Hicks M; Mclachlan AJ; Stocker S; Williams KM, 2007, 'Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol', Clinical Pharmacokinetics, vol. 46, pp. 623 - 644, http://dx.doi.org/10.2165/00003088-200746080-00001
2007
Lu CY; Williams KM; Day RO, 2006, 'Accessing health outcome data on high-cost medicines in Australia', Medical Journal of Australia, vol. 184, pp. 411 - 413
2006
Lu CY; Williams KM; Day RO, 2006, 'Access to high-cost medicines for the treatment of rheumatoid arthritis under Australia's pharmaceutical benefits scheme', Pharmacoepidemiology and Drug Safety, vol. 15, pp. S213 - S213, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000240281200458&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
2006
Lu CY; Williams KM; Day RO, 2006, 'Utilisation of anti-rheumatic drugs in Australia: Impact of introducing high-cost biologics under the pharmaceutical benefits scheme', Pharmacoepidemiology and Drug Safety, vol. 15, pp. S213 - S213, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000240281200457&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
2006
Loboz K; Gross AS; Williams KM; Liauw WS; Day RO; Blievernicht J; Zanger U; McLachlan AJ, 2006, 'Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: Effect of induction by rifampin and ethnicity', Clinical Pharmacology and Therapeutics, vol. 80, pp. 75 - 84, http://dx.doi.org/10.1016/j.clpt.2006.03.010
2006
Lu CY; Williams KM; Day RO, 2006, 'Access to tumour necrosis factor inhibitors for rheumatoid arthritis treatment under the Australian Pharmaceutical Benefits Scheme: are we on target?', Internal Medicine Journal, vol. 36, pp. 19 - 27, http://dx.doi.org/10.1111/j.1445-5994.2005.00992.x
2006
Mallon PW; Unemori P; Sedwell R; Morey AL; Rafferty M; Williams KM; Chisholm DJ; Samaras K; Emery S; Kelleher AD; Cooper DA; Carr AD, 2005, 'In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA', Journal of Infectious Diseases, vol. 191, pp. 1686 - 1696, http://dx.doi.org/10.1086/429697
2005
Jiang X; Williams KM; Liauw WS; Ammit A; Roufogalis B; Duke C; Day RO; McLachlan AJ, 2005, 'Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects', British Journal of Clinical Pharmacology, vol. 59, pp. 425 - 432, http://dx.doi.org/10.1111/j.1365-2125.2005.02322.x
2005
Lu CY; Ritchie JE; Williams KM; Day RO, 2005, 'Recent developments in targeting access to high cost medicines in Australia', Australia and New Zealand Health Policy, vol. 2, pp. 1 - 8, http://dx.doi.org/10.1186/1743-8462-2-28
2005
Mallon PW; Sedwell R; Unemori P; Rafferty M; Williams KM; Chisholm DJ; Samaras K; Emery S; Kelleher AD; Cooper DA; Carr AD, 2004, 'Changes in nuclear gene expression resulting from NRTI-induced inhibition of mitochondrial transcription reveal links between mitochondrial dysfunction and lipid metabolism', Antiviral Therapy, vol. 9, pp. L56 - L56, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000231616000125&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
2004
Mallon PW; Unemori P; Sedwell R; Morey AL; Rafferty M; Williams KM; Chisholm DJ; Samaras K; Emery S; Kelleher AD; Cooper DA; Carr AD, 2004, 'In vivo nucleoside reverse transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes independent to HIV infection', Antiviral Therapy, vol. 9, pp. L11 - L11, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000231616000044&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
2004
Jiang X; Williams KM; Liauw WS; Ammit AJ; Roufogalis BD; Duke CC; Day RO; McLachlan AJ, 2004, 'Erratum: Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects (British Journal of Clinical Pharmacology (2004) 57 (592-599))', British Journal of Clinical Pharmacology, vol. 58, pp. 102, http://dx.doi.org/10.1111/j.1365-2125.2004.02155.x
2004
Williams KM, 2004, 'Stereoselective disposition of ibuprofen enantiomers in man - Author's commentary', British Journal of Clinical Pharmacology, vol. 58, pp. S765 - S766
2004
Pett SL; Williams LA; Day RO; Lloyd AR; Carr AD; Clezy KR; Emery S; Kaplan E; Mcphee D; Mclachlan AJ; Gelder F; Lewin S; Liauw WS; Williams KM, 2004, 'A phase I study of the pharmacokinetics and safety of passive immunotherapy with caprine anti-HIV antibodies, (PE)HRG214, in HIV-1-infected individuals', HIV Clinical Trials, vol. 5, pp. 91 - 98, http://dx.doi.org/10.1310/1FLN-8KFC-5HEQ-K19J
2004
Lu CY; Williams KM; March LM; Bertouch JV; Day RO, 2004, 'Subsided access to TNF alpha inhibitors: is the rationale for exclusion of rheumatoid-factor-negative patients defensible?', Medical Journal of Australia, vol. 181, pp. 457 - 457
2004
Mallon PW; Sedwell R; Unemori P; Merlin K; McGinley C; Ammaranond P; Peperias M; Rafferty M; Williams KM; Samaras K; Morey AL; Chisholm DJ; Kelleher AD; Cooper DA; Carr AD, 2004, 'Nucleoside reverse transcriptase inhibitors (NRTI) decrease adipocyte and monocyte mitochondrial (mt) messenger RNA transcription in the absence of changes in mtDNA or cell morphology', Antiviral Therapy, vol. 9, pp. L56 - L57, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000231616000126&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
2004
Lee EJ; Williams KM; Day RO; Graham GG; Champion D, 2004, 'Stereoselective disposition of ibuprofen enantiomers in man (Reprintedfrom Br J Clin Pharmacol, vol 19, pg 669-674, 1985)', British Journal of Clinical Pharmacology, vol. 58, pp. S759 - S764, http://dx.doi.org/10.1111/j.1365-2125.2004.02288.x
2004
Lu CY; Williams KM; Day RO; March LM; Sansom L; Bertouch JV, 2004, 'Access to high cost drugs in Australia', British Medical Journal: Clinical Research, vol. 329, pp. 415 - 416
2004
Liauw WS; Williams KM; Day RO, 2004, 'Protocol Appraisal: A Study Site's Viewpoint', Applied Clinical Trials, vol. 13, pp. 34 - 42
2004
Jiang XM; Williams KM; Liauw WS; Ammit A; Roufogalis B; Duke C; Day RO; Mclachlan AJ, 2004, 'Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects', British Journal of Clinical Pharmacology, vol. 57, pp. 592 - 599, http://dx.doi.org/10.1111/j.1365-2125.2003.02051.x
2004
Jiang XM; Williams KM; Liauw WS; Ammit A; Roufogalis B; Duke C; Day RO; Mclachlan AJ, 2004, 'Pharmacokinetic-pharmacodynamic modelling to investigate herb-drug interactions with warfarin', Clinical and Experimental Pharmacology and Physiology, vol. 31, pp. A227 - A227, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000225490400052&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
2004
Lomas M; Liauw WS; Packham D; Williams KM; Kelleher AD; Zaunders J; Ward RL, 2004, 'Phase I clinical trial of a human idiotypic p53 vaccine in patients with advanced malignancy', Annals of Oncology, vol. 15, pp. 324 - 329, http://dx.doi.org/10.1093/annonc/mdh053
2004
Wren BG; Day RO; Mclachlan AJ; Williams KM, 2003, 'Pharmacokinetics of estradiol, progesterone, testosterone and dehydroepiandrosterone after transbuccal administration to postmenopausal women', Climacteric, vol. 6, pp. 104 - 111, http://dx.doi.org/10.1080/cmt.6.2.104.111
2003
Sasongko L; Williams KM; Day RO; Mclachlan AJ, 2003, 'Human subcutaneous tissue distribution of fluconazole: comparison of microdialysis and suction blister techniques', British Journal of Pharmacology, vol. 56, pp. 551 - 561, http://dx.doi.org/10.1046/j.1365-2125.2003.01930.x
2003
Sasongko L; Ramzan I; Williams KM; McLachlan AJ, 2002, 'Muscle distribution of the neuromuscular blocker gallamine using microdialysis', Journal of Pharmaceutical Sciences, vol. 91, pp. 769 - 775, http://dx.doi.org/10.1002/jps.10082
2002
Sasongko L; Ramzan I; Williams KM; Mclachlan AJ, 2001, 'Application of a high-performance liquid chromatographic assay for the neuromuscular blocker gallamine to analysis of rat plasma, muscle and microdialysate samples', Journal of Chromatography B, vol. 754, pp. 467 - 475, http://dx.doi.org/10.1016/S0378-4347(01)00032-9
2001
Williams KM; Cooper S; Parisis K; Handel M; Day RO, 2001, 'The skin suction blister: A human model of inflammation', Clinical Pharmacology and Therapeutics, vol. 69
2001
Sasongko L; Williams KL; Ramzan I; Mclachlan AJ, 2000, 'Assessment of in vitro in vivo recovery of gallamine using microdialysis', Journal of Pharmacological and Toxicological Methods, vol. 44, pp. 519 - 525, http://dx.doi.org/10.1016/S1056-8719(00)00117-9
2000
Davies NP; Mclachlan AJ; Day RO; Williams KM, 2000, 'Clinical pharmacokinetics and pharmacodynamics of celecoxib: A selective cyclo-oxygenase-2 inhibitor.', Clinical Pharmacokinetics, vol. 38, pp. 225 - 242, http://dx.doi.org/10.2165/00003088-200038030-00003
2000
Erb K; Brugger R; Williams KM; Geisslinger G, 1999, 'Stereoselective disposition of tiaprofenic acid enantiomers in rats', Chirality, vol. 11, pp. 103 - 108
1999
Day RO; Mclachlan AJ; Graham GG; Williams KM, 1999, 'Pharmacokinetics of non-steroidal anti-inflammatory drugs in synovial fluid', Clinical Pharmacokinetics, vol. 36, pp. 191 - 210, http://dx.doi.org/10.2165/00003088-199936030-00002
1999
Browne GS; Nelson CJ; Nguyen TM; Ellis B; Day RO; Williams KM, 1999, 'Stereoselective and substrate-dependent inhibition of hepatic mitochondrial B-oxidation and oxidative phosphorylation by the non-steroidal anti-inflammatory drugs ibuprofen, flurbiprofen and ketorolac', Biochemical Pharmacology, vol. 57, pp. 837 - 844, http://dx.doi.org/10.1016/S0006-2952(98)00342-6
1999
Williams KM; Day RO; Roberts LK; Harbin JA, 1999, 'A comparison of the efficacy of α-ketobutyric acid (KBA), nordihidro-guaiaretic acid (NDGA), salicylic acid (SA), and placebo (P) in the accelerated removal of corns', Clinical Pharmacology and Therapeutics, vol. 65, pp. 122, http://dx.doi.org/10.1016/S0009-9236(99)80022-8
1999
Day RO; Williams KM; Campbell TJ, 1998, 'The death of a normal healthy volunteer in a human research project: implications for Australian clinical research', Medical Journal of Australia, vol. 168, pp. 449 - 451
1998
Scheuerer S; Hall ST; Williams KM; Geisslinger G, 1998, 'Effect of clofibrate on the chiral inversion of ibuprofen in healthy volunteers', Clinical Pharmacology and Therapeutics, vol. 64, pp. 168 - 176, http://dx.doi.org/10.1016/S0009-9236(98)90150-3
1998
Scheuerer S; Williams KM; Brugger R; Mclachlan AJ; Brune K; Day RO; Geisslinger G, 1998, 'Effect of clofibrate on the chiral inversion of ibuprofen in rats', Journal of Pharmacology and Experimental Therapeutics, vol. 284, pp. 1132 - 1138
1998
Campbell TJ; Williams KM, 1998, 'Therapeutic drug monitoring: Antiarrhythmic drugs', British Journal of Clinical Pharmacology, vol. 46, pp. 307 - 319, http://dx.doi.org/10.1046/j.1365-2125.1998.t01-1-00768.x
1998
Campbell TJ; Williams KM, 1998, 'Therapeutic Drug monitoring of antiarrhythmic drugs', British Journal of Clinical Pharmacology, vol. 52, pp. 307 - 319
1998
Donnelly R; Williams KM; Baker A; Badcock CA; Day RO; Seale JP, 1997, 'Effects of budesonide and fluticasoue on 24-hour plasma cortisol: A dose-response study.', American Journal of Respiratory and Critical Care Medicine, vol. 156, pp. 1746 - 1751, http://dx.doi.org/10.1164/ajrccm.156.6.9703003
1997
Wang X; Liu Y; Nair UB; Armstrong DW; Ellis B; Williams KM, 1997, 'Enantiomeric composition of monoterpenes in conifer resins', Tetrahedron - Asymmetry, pp. 3977 - 3984
1997
Williams KM; Turner J; Geisslinger G; Day RO, 1997, 'The suction blister as an in vivo model of inflammation: Interblister variability and preliminary studies of the disposition of methotrexate', Clinical Pharmacology and Therapeutics, vol. 61, pp. 160
1997
Williams KM; Turner J; Geisslinger G; Day RO, 1997, 'The suction blister as an in vivo model of inflammation: Interblister variability and preliminary studies of the disposition of methotrexate', CLINICAL PHARMACOLOGY & THERAPEUTICS, vol. 61, pp. PI93 - PI93, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1997WJ68400093&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
1997
Oelkers R; Neupert W; Williams KM; Brune K; Geisslinger G, 1997, 'Disposition and effects of Flurbiprofen enantiomers in human serum and blister fluid', British Journal of Clinical Pharmacology, vol. 43, pp. 145 - 153
1997
Zachara NE; Packer H; Temple MD; Slade M; Jardine RJ; Karuso P; Moss CJ; Mabbutt BC; Curmi PM; Williams KM; Gooley AA, 1996, 'Recombinant prespore-specific antigen from Dictyostelium discoideum is a B-sheet glycoprotein with a spacer peptide modified by O-linked N-acetyglucosamine', European Journal of Biochemistry, vol. 238, pp. 511 - 518, http://dx.doi.org/10.1111/j.1432-1033.1996.0511z.x
1996
Soong R; Knowles S; Williams KM; Hammond IG; Wysocki SJ; Iacopetta BJ, 1996, 'Overexpression of p53 protein is an independent prognostic indicator in human endometrial carcinoma', British Journal of Cancer, pp. 562 - 567
1996
Day RO; Williams KM; Geisslinger G, 1996, 'Naproxen concentrations in plasma and synovial fluid and effects on prostanoid concentrations - Reply', JOURNAL OF RHEUMATOLOGY, vol. 23, pp. 1827 - 1828, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1996VL78300035&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
1996
Simkin PA; Bassett JE; Lapicque F; Bertin P; Netter P; Day RO; Williams KM; Geisslinger G, 1996, 'Naproxen concentration in plasma and synovial fluid and effects on prostanoid concentrations [1]', Journal of Rheumatology, vol. 23, pp. 1826 - 1828
1996
Mclachlan AJ; Williams KM, 1995, 'Estimation of the rate and extent of chiral inversion using linear systems analysis', Chirality, vol. 7, pp. 632 - 635, http://dx.doi.org/10.1002/chir.530070814
1995
Day RO; Francis H; Vial J; Geisslinger G; Williams KM, 1995, 'Naproxen concentrations in plasma and synovial fluid and effects on prostanoid concentrations', Journal of Rheumatology, vol. 22, pp. 2295 - 2303
1995
Walsh BR; Gooley AA; Williams KM; Breit SN, 1995, 'Identification of macrophage activation associated proteins by two-dimensional gel electrophoresis and microsequencing', Journal of Leukocyte Biology, vol. 57, pp. 507 - 512, http://dx.doi.org/10.1002/jlb.57.3.507
1995
Wasinger VC; Cordwell SJ; Poljak A; Yan JX; Gooley AA; Wilkins MR; Duncan MW; Harris RI; Williams KM; Humphery-Smith I, 1995, 'Progress with gene-product mapping of the mollicutes: mycroplasma genitalium', Electrophoresis, vol. 16, pp. 1090 - 1094, http://dx.doi.org/10.1002/elps.11501601185
1995
Day RO; Francis H; Vial JH; Geisslinger G; Williams KM, 1995, 'Pharmacokinetics and pharmacodynamics of naproxen in synovial fluid and plasma', Journal of Rheumatology, pp. 2295 - 2303
1995
Cordwell SJ; Wilkins MR; Poljak A; Gooley AA; Duncan MW; Williams KM; Humphery-Smith I, 1995, 'Cross-species identification of proteins separated by two-dimensional gel electrophoresis using MALDI-TOF mass spectrometry and amino acid composition', Electrophoresis, vol. 16, pp. 438 - 443, http://dx.doi.org/10.1002/elps.1150160171
1995
Day RO; Geisslinger G; Paull P; Williams KM, 1995, 'The effect of tenoxicam on tolbutamide pharmacokinetics and glucose concentrations in healthy volunteers', International journal of clinical pharmacology, vol. 33, pp. 308 - 310
1995
Seideman P; Lohrer F; Graham G; Duncan M; Williams K; Day R, 1994, 'The stereoselective disposition of the enantiomers of ibuprofen in blood, blister and synovial fluid.', British Journal of Clinical Pharmacology, vol. 38, pp. 221 - 227, http://dx.doi.org/10.1111/j.1365-2125.1994.tb04345.x
1994
Day R; Geisslinger G; Paull P; Williams K, 1994, 'Neither cimetidine nor probenecid affect the pharmacokinetics of tenoxicam in normal volunteers.', British Journal of Clinical Pharmacology, vol. 37, pp. 79 - 81, http://dx.doi.org/10.1111/j.1365-2125.1994.tb04244.x
1994
Day RO; Brooks PM; Williams KM; Graham GG, 1993, 'Third World conference on variability in response to anti-rheumatic drugs, Singapore, July 22-24, 1992.', Agents and actions, vol. 38
1993
Williams KM, 1993, 'Chiral NSAIDs: So what?', Agents and Actions, vol. 44, pp. 15 - 22
1993
Williams KM; Day RO; Breit SN, 1993, 'Biochemical actions and clinical pharmacology of anti-inflammatory drugs', Advances in Drug Research, vol. 24, pp. 121 - 198
1993
DAY RO; NGUYEN T; WILLIAMS KM, 1993, 'TENOXICAM DOSE CONCENTRATION RESPONSE RELATIONSHIP IN RHEUMATOID-ARTHRITIS (RA)', CLINICAL PHARMACOLOGY & THERAPEUTICS, vol. 53, pp. 152 - 152, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1993KP26900067&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
1993
Day RO; Brooks PM; Williams KM; Graham GG, 1993, 'Meeting report: Third world conference on variability in response to anti-rheumatic drugs, Singapore, July 22-24, 1992', Agents and Actions, vol. 38
1993
Brooks PM; Day RO; Graham GG; Williams KM, 1993, 'Preface', Agents and Actions, vol. 44
1993
Zhao B; Geisslinger G; Hall I; Day RO; Williams KM, 1992, 'The effect of the enantiomers of ibuprofen and flurbiprofen on the β‐oxidation of palmitate in the rat', Chirality, vol. 4, pp. 137 - 141, http://dx.doi.org/10.1002/chir.530040302
1992
Williams KM, 1991, 'Molecular Asymmetry and Its Pharmacological Consequences', Advances in Pharmacology, vol. 22, pp. 57 - 135, http://dx.doi.org/10.1016/S1054-3589(08)60033-2
1991
Knihinicki RD; Day RO; Williams KM, 1991, 'Chiral inversion of 2-arylpropionic acid non-steroidal anti-inflammatory drugs-II Racemization and hydrolysis of (R)- and (S)-ibuprofen-CoA thioesters', Biochemical Pharmacology, vol. 42, pp. 1905 - 1911, http://dx.doi.org/10.1016/0006-2952(91)90588-V
1991
Williams KM; Knihinicki RD; Day RO, 1991, 'Pharmacokinetics of the enantiomers of ibuprofen in the rabbit', Agents and Actions, vol. 34, pp. 381 - 386, http://dx.doi.org/10.1007/BF01988732
1991
Day RO; Williams KM; Graham S; Handel M, 1991, 'The pharmacokinetics of total and unbound concentrations of tenoxicam in synovial fluid and plasma', Arthritis & Rheumatism, vol. 34, pp. 751 - 760, http://dx.doi.org/10.1002/art.1780340617
1991
Williams KM, 1990, 'Enantiomers in arthritic disorders', Pharmacology and Therapeutics, vol. 46, pp. 273 - 295, http://dx.doi.org/10.1016/0163-7258(90)90095-J
1990
Lee EJD; Willia KM, 1990, 'Chirality Clinical Pharmacokinetic and Pharmacodynamic Considerations', Clinical Pharmacokinetics, vol. 18, pp. 339 - 345, http://dx.doi.org/10.2165/00003088-199018050-00001
1990
Knihinicki RD; Day RO; Graham GG; Williams KM, 1990, 'Stereoselective disposition of ibuprofen and flurbiprofen in rats', Chirality, vol. 2, pp. 134 - 140, http://dx.doi.org/10.1002/chir.530020303
1990
Nuernberg B; Knihinicki R; Williams K; Freeman GE; Dalton C; Brooks PM; Day RO, 1990, 'Anti-inflammatory effects and disposition of S- and R-flurbiprofen in the rat', European Journal of Pharmacology, vol. 183, pp. 1591 - 1592, http://dx.doi.org/10.1016/0014-2999(90)94757-O
1990
Knihinicki RD; Williams KM; Day RO, 1989, 'Chiral inversion of 2-arylpropionic acid non-steroidal anti-inflammatory drugs-1. In vitro studies of ibuprofen and flurbiprofen', Biochemical Pharmacology, vol. 38, pp. 4389 - 4395, http://dx.doi.org/10.1016/0006-2952(89)90647-3
1989
Williams KM, 1989, 'CHIRALITY: PHARMACOKINETICS AND PHARMACODYNAMICS IN 3 DIMENSIONS', Clinical and Experimental Pharmacology and Physiology, vol. 16, pp. 465 - 470, http://dx.doi.org/10.1111/j.1440-1681.1989.tb01589.x
1989
Williams KM; Day RO, 1988, 'The contribution of enantiomers to variability in response to anti-inflammatory drugs.', Agents and actions. Supplements, vol. 24, pp. 76 - 84
1988
Day RO; Williams KM; Graham GG; Lee EJ; Knihinicki RD; Champion GD, 1988, 'Stereoselective disposition of ibuprofen enantiomers in synovial fluid', Clinical Pharmacology and Therapeutics, vol. 43, pp. 480 - 487, http://dx.doi.org/10.1038/clpt.1988.62
1988
Day R; Paull P; Lam S; Swanson B; Williams K; Wade D, 1988, 'The effect of concurrent aspirin upon plasma concentrations of tenoxicam.', British Journal of Clinical Pharmacology, vol. 26, pp. 455 - 462, http://dx.doi.org/10.1111/j.1365-2125.1988.tb03405.x
1988
Day RO; Graham GG; Williams KM, 1988, 'Pharmacokinetics of non-steroidal anti-inflammatory drugs', Bailliere's Clinical Rheumatology, vol. 2, pp. 363 - 393, http://dx.doi.org/10.1016/S0950-3579(88)80019-0
1988
Day RO; Graham GG; Willia KM; Brooks PM, 1988, 'Variability in Response to NSAIDs: Fact or Fiction?', Drugs, vol. 36, pp. 643 - 651, http://dx.doi.org/10.2165/00003495-198836060-00001
1988
Day RO; Graham GG; Williams KM; David Champion G; de Jager J, 1987, 'Clinical pharmacology of non-steroidal anti-inflammatory drugs', Pharmacology and Therapeutics, vol. 33, pp. 383 - 433, http://dx.doi.org/10.1016/0163-7258(87)90072-6
1987
WILLIAMS KM; DAY RO; KNIHINICKI RD; DUFFIELD AM, 1986, 'STEREOSELECTIVE INCORPORATION OF IBUPROFEN ENANTIOMERS INTO ADIPOSE-TISSUE IN RATS AND MAN', ACTA PHARMACOLOGICA ET TOXICOLOGICA, vol. 59, pp. 192 - 192, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1986D896000552&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
1986
Williams K; Day R; Knihinicki R; Duffield A, 1986, 'The stereoselective uptake of ibuprofen enantiomers into adipose tissue', Biochemical Pharmacology, vol. 35, pp. 3403 - 3405, http://dx.doi.org/10.1016/0006-2952(86)90443-0
1986
Lee E; Williams K; Day R; Graham G; Champion D, 1985, 'Stereoselective disposition of ibuprofen enantiomers in man.', British Journal of Clinical Pharmacology, vol. 19, pp. 669 - 674, http://dx.doi.org/10.1111/j.1365-2125.1985.tb02694.x
1985
Williams KM; Day RO, 1985, 'Stereoselective disposition--basis for variability in response to NSAID's.', Agents and actions. Supplements, vol. 17, pp. 119 - 126
1985
DAY RO; WILLIAMS KM; LEE EJ; KNIHINICKI R, 1985, 'DISPOSITION OF ENANTIOMERS OF IBUPROFEN IN PLASMA AND SYNOVIAL-FLUID IN ARTHRITIC DISEASE', CLINICAL AND INVESTIGATIVE MEDICINE-MEDECINE CLINIQUE ET EXPERIMENTALE, vol. 8, pp. A58 - A58, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1985AQS8500134&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
1985
Williams KM, 1984, 'Kinetics of misonidazole enantiomers', Clinical Pharmacology and Therapeutics, vol. 36, pp. 817 - 823, http://dx.doi.org/10.1038/clpt.1984.262
1984
Lee EJD; Williams KM; Graham GG; Day RO; Champion GD, 1984, 'Liquid chromatographic determination and plasma concentration profile of optical isomers of ibuprofen in humans', Journal of Pharmaceutical Sciences, vol. 73, pp. 1542 - 1544, http://dx.doi.org/10.1002/jps.2600731112
1984
Begg E; Williams K; Wade D; O'Shea K, 1983, 'No significant effect of cimetidine on the pharmacokinetics of misonidazole in man.', British Journal of Clinical Pharmacology, vol. 15, pp. 575 - 576, http://dx.doi.org/10.1111/j.1365-2125.1983.tb02096.x
1983
WILLIAMS KM; BEGG EJ; WADE DN; OSHEA K, 1983, 'THE EFFECT OF CIMETIDINE AND METOCLOPRAMIDE ON THE ELIMINATION OF MISONIDAZOLE (RO-07-0582) IN MAN', CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, vol. 10, pp. 718 - 719, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1983RW31100131&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
1983
Williams K; Begg E; Wade D; O'Shea K, 1983, 'Effects of phenytoin, phenobarbital, and ascorbic acid on misonidazole elimination', Clinical Pharmacology and Therapeutics, vol. 33, pp. 314 - 321, http://dx.doi.org/10.1038/clpt.1983.39
1983
Williams K; Begg E; Wade D; O'Shea K, 1983, 'No significant effect of metoclopramide on misonidazole elimination in man.', British Journal of Clinical Pharmacology, vol. 15, pp. 390 - 392, http://dx.doi.org/10.1111/j.1365-2125.1983.tb01519.x
1983
BEGG EJ; WILLIAMS KM; WADE DN; OSHEA KF, 1983, 'NO SIGNIFICANT EFFECT OF CIMETIDINE ON THE PHARMACOKINETICS OF MISONIDAZOLE IN MAN', BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, vol. 15, pp. 575 - 576, http://dx.doi.org/10.1111/j.1365-2125.1983.tb02096.x
1983
Williams KM; Begg EJ; Wade DN; O'Shea K, 1982, 'The effect of phenytoin, phenobarbitone and ascorbic acid on the elimination of misonidazole (Ro 07-0582) in man', Clinical and Experimental Pharmacology and Physiology, vol. 9, pp. 423
1982
Tung C; Graham GG; Wade DN; Williams KM, 1982, 'The pharmacokinetics of chlorbutol in man', Biopharmaceutics & Drug Disposition, vol. 3, pp. 371 - 378, http://dx.doi.org/10.1002/bdd.2510030410
1982
CHINWAY PM; WILLIAMS KM; WADE DN, 1982, 'A STUDY OF THE DISTRIBUTION AND ELIMINATION OF HIGH-DOSES OF DPH IN RABBITS', CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, vol. 9, pp. 459 - 460, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1982PJ26400121&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
1982
Williams KM; Duffield AM; Christopher RK; Finlayson PJ, 1981, 'Identification of minor metabolites of 5‐fluorocytosine in man by chemical ionization gas chromatography mass spectrometry', Biological Mass Spectrometry, vol. 8, pp. 179 - 182, http://dx.doi.org/10.1002/bms.1200080410
1981
WILLIAMS KM; DUFFIELD AM; CHRISTOPHER RK; FINLAYSON PJ, 1980, 'MINOR METABOLITES OF 5-FLUOROCYTOSINE IN MAN', CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, vol. 7, pp. 681 - 681, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1980KV12600077&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
1980
TUNG C; GRAHAM GG; WADE DN; WILLIAMS KM, 1980, 'THE PHARMACOKINETICS OF CHLORBUTOL', CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, vol. 7, pp. 672 - 672, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1980KV12600062&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
1980
BORODY T; CHINWAH PM; GRAHAM GG; WADE DN; WILLIAMS KM, 1979, 'CHLORBUTOL TOXICITY AND DEPENDENCE', MEDICAL JOURNAL OF AUSTRALIA, vol. 1, pp. 288 - 288, http://dx.doi.org/10.5694/j.1326-5377.1979.tb112109.x
1979
Conference Papers
add
Martinello M; Schteinman A; Alavi M; Williams K; Dore GJ; Day R; Matthews GV, 2016, 'The impact of ribavirin plasma concentration on the eficacy of the interferon-sparing regimen, sofosbuvir and ribavirin', in Antiviral Therapy, pp. 127 - 132, http://dx.doi.org/10.3851/IMP2984
2016
Franklin ME; Anderson JM; Stocker SL; Pillans PI; Williams KM; Day RO; Taylor PJ, 2009, 'Measurement of Oxypurinol Concentrations in Urine by HPLC-Tandem Mass Spectrometry', in THERAPEUTIC DRUG MONITORING, LIPPINCOTT WILLIAMS & WILKINS, Montreal, CANADA, pp. 640 - 640, presented at 11th International Congress of Therapeutic Drug Monitoring and Clinical Toxicology, Montreal, CANADA, 03 October 2009 - 08 October 2009, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000270484600142&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2009
Day RO; Mclachlan AJ; Williams KM, 1998, 'Population pharmacokinetics (PK) and pharmacodynamics (PD) of tenoxicam (TN) in patients with rheumatoid arthritis (RA)', in Clinical Pharmacology and Therapeutics, Mosby, St Louis, MO, USA, pp. 168, presented at Clinical and Pharmacology Therapeutics, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000072420300125&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
1998
Williams KM; Ray J; Gengos D; Duffull SB; Palmer P; Fuller A, 1998, 'A comparative assessment of the safety of a new lignocaine suppository for the treatment of painful hemorrhoids', in Clinical Pharmacology and Therapeutics, Mosby, St Louis, MO, USA, pp. 147, presented at Clinical and Pharmacology Therapeutics, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000072420300042&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
1998
Williams KM; Mclachlan AJ; Day RO; Pritchard A, 1998, 'Comparative pharmacokinetics of hepatitis B immuno-globulin after intramuscular administration in healthy subjects', in Naunyn - Schmiedebergs Archives of Pharmacology, Springer, New York, NY, USA, pp. 285, presented at Archives of Pharmacology 358, Munich, Germany, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000075207701061&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
1998
Ziegler JB; Graham GG; Day RO; Williams KM; Milligan MK, 1997, 'THERAPEUTIC CONSIDERATIONS FROM PHARMACOKINETICS AND METABOLISM: IBUPROFEN AND PARACETAMOL.', in Safety and Efficacy of non-prescription (OTC) analgesics and NSAIDs, Kluwer Academic Publishers, Dordrecht, presented at Safety and Efficacy of non-prescription analgesics and NSAIDS, San Francisco, California USA, 17 March 1997 -
1997
Conference Posters
add
Vaccher S; Kannangara D; Baysari M; Zwar N; Reath J; Williams K; Day R, 2014, 'Barriers to care in gout: A qualitative study of patients’ and prescribers’ understanding and management', Melbourne, Australia, presented at ASCEPT Scientific Meeting, Melbourne, Australia, 07 December 2014
2014
Matthews GV; Kaur A; Ray JE; Graham GG; Egan B; Williams KM; Day RO, 2013, 'USE OF A POPULATION PHARMACOKINETIC MODEL TO PREDICT WEEK 4 RIBAVIRIN LEVELS FROM EARLY CONCENTRATIONS', Amsterdam, NETHERLANDS, Vol. 58, pp. S357 - S357, presented at International Liver Congress / 48th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Amsterdam, NETHERLANDS, 24 April 2013 - 28 April 2013, http://dx.doi.org/10.1016/S0168-8278(13)60872-7
2013
Day RO; Walker JS; Seideman P; Knihinicki RD; Williams K, 1990, 'A human model for evaluation of non-steroidal anti-inflammatory drug (NSAID) distribution into extracellular fluid', Vol. 183, pp. 1034, http://dx.doi.org/10.1016/0014-2999(90)92891-L
1990
Book Chapters
add
Day RO; Williams KM; Graham GG, 2013, 'Urate-lowering therapy: Uricosurics', in Dalbeth N; Peresa-Ruiz F; Schlesinger N (ed.), Gout, Future Medicine Ltd, pp. 174 - 188, http://dx.doi.org/10.2217/ebo.13.104
2013
Day RO; Graham GG; Williams KM, 2013, 'Propionic acid derivative drugs (Profens)', in Encyclopedia of Inflammatory Diseases, Springer-Verlag, Berlin Heidelberg, http://www.springerreference.com/
2013
Bachmeier CJ; Brooks PM; Day RO; Graham GG; Littlejohn GO; Morand E; Pile K; Williams KM, 2005, 'Disease-modifying anti-rheumatic drugs (DMARD)', in Nijkamp FJ; Parnham MJ (ed.), Principles of Immunopharmacology (2nd Ed), edn. 2nd, Birkhauser Verlag, Basel, pp. 511 - 544
2005
Day RO; Quinn DI; March LM; Graham GG; Williams KM, 2000, 'Rheumatoid arthritis. New Frontiers in pathogenesis and treatment', in NSAIDs and analgesics, edn. Original, Oxford University Press, Oxford, England, pp. 307 - 328
2000
Bachmeier CJ; Handel ML; Conaghan PG; Williams KM; Graham GG; Brooks PM; Day RO, 1999, 'Disease-modifying antirheumatic drugs', in Nijkamp FP; Parnham MJ (ed.), Principles of Immunopharmacology, edn. 3, Birkhauser Verlag (Springer), Basel, Switzerland, pp. 379 - 403
1999
Graham GG; Milligan MK; Day RO; Williams KM; Ziegler JB, 1998, 'Therapeutic considerations from pharmacokinetics and metabolism: ibuprofen and paracetamol', in Rainsford KD; Powanda MC (ed.), Safety and Efficacy of non-prescription (OTC) analgesics and NSAIDs, Kluwer Academic Publishers, Dordrecht, pp. 77 - 92, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000081416000006&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
1998
Bachmeier CJ; Handel ML; Conaghan PG; Williams KM; Graham GG; Brooks PM; Day RO, 1998, 'Disease Modifying antirheumatic drugs', in Textbook of Immunopharmacology, edn. 3, Burkhauser, Basel, Switzerland, pp. 183 - 190, http://dx.doi.org/10.1097/00002281-199705000-00003
1998
Graham GG; Milligan MK; Day RO; Williams KM; Zeig , 1997, 'Therapeutic considerations from pharmacokinetics and metabolism: ibuprofen and paracetamol', in In: `Safety and efficacy of non-prescription (OTC) analgesics, edn. Original, Kluwer Academic Publishers, Great Britain, pp. 77 - 92
1997
Vesey G; Ashbolt NJ; Wallner G; Dorsch R; Williams KM; Veal DA, 1995, 'Assessing cryptosporidium parvum oocyst viability with fluorescent in situ hybridization using ribosomal RNA probes and flow cytometry', in Protozoan parasites and water, edn. Original, Royal Society of Chemistry, Cambridge, pp. 133 - 138
1995